Centro Clinico Nemo

The research at Centro Clinico Nemo emphasizes rare genetic disorders that affect muscle development and function, including Duchenne Muscular Dystrophy, Spinal Muscular Atrophy, and Myotonic Dystrophy. Trials aim to test novel gene‑based and protein‑restoring therapies while monitoring safety and tolerability.

• Gene‑editing approaches for DMD
• Antisense oligonucleotide studies in SMA
• Small‑molecule modifiers for myotonia
• Long‑term safety monitoring of emerging treatments

Ongoing studies provide hope for patients and families by seeking to improve motor outcomes and quality of life in these congenital conditions.

Investigations target progressive muscle‑wasting conditions such as Facioscapulohumeral Muscular Dystrophy and amyotrophic lateral sclerosis, focusing on slowing decline and preserving strength. The primary goal is to evaluate efficacy of investigational drugs that modulate muscle metabolism or reduce pathological protein aggregation.

• HDAC inhibition in non‑ambulant DMD
• Anti‑inflammatory agents for FSHD
• Neuroprotective compounds for ALS
• Functional mobility assessments in trial cohorts

By integrating imaging biomarkers and functional tests, the site aims to generate robust data that could translate into better therapeutic options for patients with debilitating muscle disorders.

The center conducts trials on neurodegenerative illnesses such as Amyotrophic Lateral Sclerosis and advanced forms of Spinal Muscular Atrophy, seeking to halt neuronal loss and improve respiratory and motor function. Research emphasizes safety, pharmacokinetics, and measurable clinical benefit of emerging agents.

• Combination therapy of risdiplam with novel agents
• High‑dose intrathecal nusinersen evaluations
• Metabolic support with acetyl‑L‑carnitine in ALS
• Biomarker development using MRI and functional scales

These studies contribute to a deeper understanding of disease mechanisms and strive to deliver treatments that extend survival and independence for affected individuals.

A dedicated research stream investigates the underlying physiology of muscle and nerve interaction, employing advanced imaging and electrophysiological tools to assess treatment impact. Projects explore how investigational compounds influence muscle protein expression, myotonia, and neural signaling pathways.

• MRI‑based quantification of muscle composition
• Electromyography for myotonia severity
• Pharmacodynamic profiling of RO7204239
• Biomarker validation for therapeutic response

Insights gained from these mechanistic studies support the design of more effective interventions across the site’s broader neuromuscular program.